Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.
Horowitz
Michael
M
Feinle-Bisset
Christine
C
Jones
Karen
K
Nauck
Michael
M
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009765:Obesity / Q000097:blood* / Q000150:complications; D000077403:Orlistat; D010446:Peptide Fragments / Q000097:blood*; D019518:Postprandial Period; D011498:Protein Precursors / Q000097:blood*
D019440:Anti-Obesity Agents; D007783:Lactones; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077403:Orlistat